Literature DB >> 28478456

Interstitial 10q21.1q23.31 Duplication due to Meiotic Recombination of a Paternal Balanced Complex Rearrangement: Cytogenetic and Molecular Characterization.

Viola Alesi1, Valeria Orlando, Silvia Genovese, Sara Loddo, Elisa Pisaneschi, Daniele Pompili, Cecilia Surace, Fabrizia Restaldi, Maria C Digilio, Bruno Dallapiccola, Maria L Dentici, Antonio Novelli.   

Abstract

Complex chromosomal rearrangements (CCRs) are structural aberrations involving more than 2 chromosomal breakpoints. They are associated with different outcomes depending on the deletion/duplication of genomic material, gene disruption, or position effects. Balanced CCRs can also undergo missegregation during meiotic division, leading to unbalanced derivative chromosomes and, in some cases, to affected offspring. We report on a patient presenting with developmental and speech delay, growth retardation, microcephaly, hypospadias, and dysmorphic features, harboring an interstitial 10q21.1q23.31 duplication, due to recombination of a paternal CCR. Application of several cytogenetic and molecular techniques allowed determining the biological bases of the rearrangement, understanding the underlying chromosomal mechanism, and assessing the reproductive risk.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Chromosome 10q; Complex chromosome rearrangement; Interstitial duplication; Meiotic recombination

Mesh:

Year:  2017        PMID: 28478456     DOI: 10.1159/000475490

Source DB:  PubMed          Journal:  Cytogenet Genome Res        ISSN: 1424-8581            Impact factor:   1.636


  1 in total

1.  A familial chromosomal complex rearrangement confirms RUNX1T1 as a causative gene for intellectual disability and suggests that 1p22.1p21.3 duplication is likely benign.

Authors:  Fabrizia Restaldi; Viola Alesi; Angela Aquilani; Silvia Genovese; Serena Russo; Valentina Coletti; Daniele Pompili; Roberto Falasca; Bruno Dallapiccola; Rossella Capolino; Matteo Luciani; Antonio Novelli
Journal:  Mol Cytogenet       Date:  2019-06-14       Impact factor: 2.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.